Outcome of AGM

(Formerly – Kilpest India Limited) Ref. No.P-66/2026-27/43 September 29, 2026 The Relationship Manager, Department of Corporate Relations BSE Ltd, P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 SUBJECT: SUMMARY OF PROCEEDINGS OF THE 54th ANNUAL GENERAL MEETING (‘AGM’) OF THE COMPANY HELD ON TUESDAY, 29TH SEPTEMBER, 2026 Dear Sir, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform that the following businesses were transacted at the 54th Annual General Meeting (“AGM”) of members of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) (“Company”) held today i.e. Tuesday, 29th September, 2026 through Video Conferencing (VC) / Other Audio Visual Means (OAVM) started at 11:30 A.M. and concluded at 12:05 P.M. Mr. Dhirendra Dubey, Chairman and Managing Director, chaired the Meeting. The requisite quorum being present, the Chairman called the Meeting to order. The Chairman addressed the members. A copy of the Investor‟s Presentation presented at the Annual General Meeting („AGM‟) held today is attached herewith. In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI Listing Regulations, the Company had provided to its members the remote e-voting facility to exercise their right to vote in respect of the resolutions proposed at the AGM, convened vide Notice dated 13th August, 2026, through e-voting platform hosted by Central Depository Services (India) Limited (CDSL) from Saturday, 26th September, 2026 (9:00 a.m. IST onwards) to Monday, 28th September, 2026 (5:00 p.m. IST). Members, who could not cast their votes through remote e-voting before the Meeting, but attended the AGM, were also provided with the facility of remote e-Voting during the AGM by CDSL. Ordinary Business 1. Adoption of Audited Standalone Financial Statements of the Company for the financial year ended 31st March 2026, the reports of the Board of Directors and Auditors. 2. Adoption of Audited Consolidated Financial Statements of the Company for the financial year ended 31st March 2026 along with the Auditors report. 3. Declaration of dividend at the rate of Rs. 5.00/- (Rupees Five only) per share on equity shares for the year ended 31st March 2026. Special Business 4. Appointment of a Director in place of Mrs. Mithla Dubey (DIN: 03597415) who retires by rotation and being eligible, offers herself for re-appointment. Regd. Office & Factory : 7-C | Industrial Area | Govindpura | Bhopal – 462023 | (M.P.) | INDIA CIN : L24211MP1972PLC001131 Ph.: 91-755-2586536, 2586537 Email : info@kilpest.com Visit us at : www.kilpest.com (Formerly – Kilpest India Limited) 5. Ratification of Remuneration of the Cost Auditor. The above businesses were transacted through remote e-voting and e-voting at the Annual General Meeting as required under the Companies Act, 2013 and SEBI Listing Regulations. Mr. Praveen Kumar Rai, Proprietor of M/s. P.K. Rai & Associates, Practicing Company Secretary, was appointed as the scrutinizer to scrutinize the remote e-voting process and e-voting process at the Annual General Meeting. Details of voting results under Regulation 44(3) of SEBI Listing Regulations will be displayed on Company’s website and shall be submitted separately to the Stock Exchanges along with Scrutinizer’s Report. Thanking you, This is for your information and records. Yours faithfully, For 3B BlackBio DX Limited (Formerly, KILPEST INDIA LTD) Navneet Kaur Company Secretary ACS No.: 29130 Encls: as above DearShareholders, It gives me great pleasure to welcome you all to the 54th Annual General Meeting of 3B BlackBio Dx Limited. Today, we come together not only to review the financial outcomes of the fiscal year 2025–26 but also to reflect on the milestones andsuccesseswe haveachievedas a collective. For more than fifty years, 3B BlackBio Dx Limited has stood as a testament to resilience and innovation, continually delivering high-quality solutions to patients, clinicians, and partners. This legacy has been possible only because of the relentless commitment of our employees, the enduring loyalty of our customers, and the steadfast support of you—our esteemedshareholders.We remaingratefulfor your unwaveringpartnership throughoutthesedecades. The company completed the acquisition of Coris BioConcept on 29th August 2025. According to the Ind AS rules, we have consolidatedthefinancials figuresof Coris fromthe dateof acquisition. With this spirit, let us now turn our attention to an overview of the company’s financial performance for the year ended 31st March 2026. Consolidated*–  Revenue fromOperations - ₹ 141.91 Crores  Profit before Tax - ₹ 76.96 Crores  Profit after Tax - ₹ 59.92 Crores  Earnings per share - ₹ 69.94 *Above figures include financials fromCoris BioConcept. These results reflect not only our robust operational strategies but also the strength of our brand in a competitive market. The detailed accounts for the year, along with the Directors’ and Auditors’ Reports, have already been circulated to you. With your permission, I would like to take them as read. Disclaimer: This presentation may contain some of the forward-looking statements which are completely based on the management's belief, opinion, and expectations as of today. These statements are not a guarantee of company's future performance and involve unforeseen risk and uncertainties. India Business In India, the company operates through three primary sales models: a) TenderSales:This accounts forapproximately 5%-7% ofthe total sales. b) Reagent Rental Model: In this model, we provide molecular diagnostic equipment to the labs / hospitals with a condition that only our assays are used, these are long-term contracts (typically signed for a duration of a minimum of 3 years) which are projected to contribute business of 20%-25% for this financial year and coming years. Currently we have over 15 contracts in place. As the model ensures 3-5 year committed business with ensured volumes, it justifies its viability. c) Other Supplies: Apart from above, we sell products to hospitals and labs which comprises the remaining 65%- 70% of the total sales. Infectious disease assays contribute approximately 60% of our sales, while oncology assays contribute around 40%. This mix may vary with growth, due to competitive reasons we do not disclose the exact sales split across individual assays. The Total Addressable Market (TAM) for Molecular Diagnostics (MDx) in India is estimated at approx. ₹500–600 Cr and we hold a 12%–15% market share, positioning ourselves among the market leaders. The MDx industry in India is projected to grow at 8%–10% CAGR over the next few years due to factors like increasing adoption of molecular diagnostics across diagnostic labs and hospitals and government projects. However, this growth is attracting increased competition which affects pricing. Even with this, we are hoping to grow at 15%–20% for FY 2026–27, backed by our extensive product portfolio and strong market presence over the years and high-quality products well accepted by the customers. Exports TRUPCR® assays have gained widespread global acceptance, with a presence in over 75 countries across Europe, Middle East, Africa, APAC, LATAM and North America. Our international footprint has expanded significantly from 25 countries in 2021, supported by a growing distribution network, new product registrations, international tenders and successful customer validations. Regulatory registrations remain central to our expansion strategy and typically take 10–15 months, depending on the country and regulatory pathway. During the year, registrations were initiated in additional countries across Latin America and Asia, creating opportunities for further growth as approvals are received. Participation in leading international exhibitions and c [Showing first 8,000 characters — download PDF for full document]